Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: A six-year population-based cohort study

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 4, 2014, Pages 354-360

  Lin, H C ^a,b   Hsu, Y T ^c   Kachingwe, B H ^c   Hsu, C Y ^c   Uang, Y S ^c   Wang, L H ^b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

cancer risk; cohort study; dose effect; thiazolidinedione; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; INSULIN DERIVATIVE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; EAR NOSE THROAT DISEASE; FEMALE; HAZARD RATIO; HUMAN; LIVER CANCER; LUNG CANCER; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT RISK; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; UTERUS CANCER; ADOLESCENT; AGED; CHILD; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; RISK; TAIWAN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TAIWAN; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84904192577     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12151     Document Type: Article

References (45)

1. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG,. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia, 2012; 55: 1607-1618.
2. McTernan PG, Anwar A, Eggo MC, Barnett AH, Stewart PM, Kumar S,. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord, 2000; 24: 875-881.
3. Mistry T, Digby JE, Desai KM, Randeva HS,. Obesity and prostate cancer: a role for adipokines. Eur Urol, 2007; 52: 46-53.
4. Barnard RJ,. Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr, 2007; 86: s889-s893.
5. Yki-Jarvinen H,. Thiazolidinediones. N Engl J Med, 2004; 351: 1106-1118.
6. Okumura T,. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol, 2010; 45: 1097-1102.
7. Colin C, Salamone S, Grillier-Vuissoz I, et al,. New troglitazone derivatives devoid of PPAR gamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res Treat, 2010; 124: 101-110.
8. Qiao L, Dai Y, Gu Q, et al,. Loss of XIAP sensitizes colon cancer cells to PPAR gamma independent antitumor effects of troglitazone and 15-PGJ2. Cancer Lett, 2008; 268: 260-271.
9. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM,. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol, 2007; 71: 1715-1720.
10. Li MY, Lee TW, Yim AP, Chen GG,. Function of PPARgamma and its ligands in lung cancer. Crit Rev Clin Lab Sci, 2006; 43: 183-202.
11. Kebebew E, Peng M, Reiff E, et al,. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery, 2006; 140: 960-966;discussion 966-967.
12. Yu J, Qiao L, Zimmermann L, et al,. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology, 2006; 43: 134-143.
13. Giovannucci E, Harlan DM, Archer MC, et al,. Diabetes and cancer: a consensus report. CA Cancer J Clin, 2010; 60: 207-221.
14. Saez E, Tontonoz P, Nelson MC, et al,. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med, 1998; 4: 1058-1061.
15. Piccinni C, Motola D, Marchesini G, Poluzzi E,. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care, 2011; 34: 1369-1371.
16. Lewis JD, Ferrara A, Peng T, et al,. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care, 2011; 34: 916-922.
17. Govindarajan R, Ratnasinghe L, Simmons DL, et al,. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol, 2007; 25: 1476-1481.
18. Ramos-Nino ME, MacLean CD, Littenberg B,. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med, 2007; 5: 17.
19. Monami M, Lamanna C, Marchionni N, Mannucci E,. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care, 2008; 31: 1455-1460.
20. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index including Defined Daily Doses (DDDs) for plain substances. Oslo: WHO CCDSM, 48-62, 2001.
21. Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S,. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis, 2006; 9: 270-274.
22. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R,. Diabetes and cancer. Endocr Relat Cancer, 2009; 16: 1103-1123.
23. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G,. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia, 2010; 53: 1838-1845.
24. Colmers IN, Bowker SL, Johnson JA,. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab, 2012; 38: 475-484.
25. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA,. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology, 2012; 55: 1462-1472.
26. Koro C, Barrett S, Qizilbash N,. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf, 2007; 16: 485-492.
27. Ferrara A, Lewis JD, Quesenberry CP, et al,. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 2011; 34: 923-929.
28. Oliveria SA, Koro CE, Ulcickas Yood M, Sowell M,. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr, 2008; 2: 47-57.
29. Tseng CH,. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia, 2011; 54: 2009-2015.
30. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR,. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care, 2010; 33: 1304-1308.
31. Wright JL, Stanford JL,. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control, 2009; 20: 1617-1622.
32. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL,. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 2009; 137: 482-488.
33. Azoulay L, Yin H, Filion KB, et al,. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ, 2012; 344: e3645.
34. Barbalat Y, Dombrovskiy VY, Weiss RE,. Association between pioglitazone and urothelial bladder cancer. Urology, 2012; 80: 1-4.
35. Tseng CH,. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care, 2012; 35: 278-280.
36. Weber MB, Oza-Frank R, Staimez LR, Ali MK, Narayan KM,. Type 2 diabetes in asians: prevalence, risk factors, and effectiveness of behavioral intervention at individual and population levels. Annu Rev Nutr, 2012; 32: 417-439.
37. Ramachandran A, Ma RC, Snehalatha C,. Diabetes in Asia. Lancet, 2010; 375: 408-418.
38. Raji A, Seely EW, Arky RA, Simonson DC,. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab, 2001; 86: 5366-5371.
39. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U,. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology, 2005; 213: 157-168.
40. Satoh T, Toyoda M, Hoshino H, et al,. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene, 2002; 21: 2171-2180.
41. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB,. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem, 2002; 277: 31781-31788.
42. Kao CH, Sun LM, Chen PC, et al,. A population-based cohort study in Taiwan-use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol, 2012; 24: 523-530.
43. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY,. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc, 2005; 104: 157-163.
44. Soranna D, Scotti L, Zambon A, et al,. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist, 2012; 17: 813-822.
45. Smith U, Gale EA,. Does diabetes therapy influence the risk of cancer? Diabetologia, 2009; 52: 1699-1708.